Skip to main content

Celonic agrees cooperation to combat coronavirus

| News

Celonic agrees cooperation to combat coronavirus

26.05.2020

The Basel-based biopharmaceutical company Celonic Group has agreed a partnership with Airway Therapeutics from the USA. Together, the two companies are planning to develop a drug to treat coronavirus.

SARS-CoV-2

The core element of the collaboration between Airway Therapeutics and Celonic is based on the novel human recombinant protein AT-100. Airway Therapeutics has developed this protein on the basis of genetic engineering. Up to now, it has shown “great potential” in fighting inflammation and serious respiratory diseases driven by infection, as detailed by Marc Salzberg, CEO of Airway Therapeutics, in a press release issued by the two firms. However, the protein has so far not been manufactured in the volumes required for clinical trials. The Basel-based Celonic Group will now be responsible for this task.

“Given the urgency of the current pandemic, I am thrilled to establish this collaboration with Celonic, a leader in biologic manufacturing”, Salzberg states. Celonic will optimize manufacturing processes within the framework of this cooperation and assume responsibility for ensuring that production processes comply with the applicable guidelines for pharmaceuticals and active substances in the requisite volume for a clinical trial. Production is to begin as early as June 2020.

At Celonic, the prevailing sentiments are of excitement and pride in the cooperation with Airway and in taking part in the fight against this global pandemic, according to Konstantin Matentzoglu, CEO of Celonic, who was quoted in the press release. “AT-100 has the potential to be a lifesaving treatment for COVID-19 patients until a vaccine is available”, he comments. Seriously ill patients and those in intensive care stand to primarily benefit from this development.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

Do you have a question? We'd like to hear from you.